At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
R932333 +1 moredrug
Likely dose
R932333 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions
In Brief
A Phase 2 clinical trial evaluating R932333 and Placebo for Lupus Erythematosus, Discoid and Lupus Erythematosus, Systemic. Completed, enrolled 54 participants across 15 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartAug 2012
Primary CompletionSep 2013
TodayJul 2026
First PostedMay 11, 2012
Enrollment StartAug 1, 2012
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.1 years ago
Interventions
R932333drug
R393233 6% (60 mg/g), bid
Placebodrug
Placebo, bid